1.Bazley LA，Gullick WJ. The epidermal growth factor receptor family. Endor Relat Cancer，2005，12 Suppl 1：S17-27.

2.Hubbard SR，Millet WT.Receptor tyrosine kinases：mechanisms of activation and signaling.Current Opinion in Cell Biology，2007，19（2）：117-123.

3.Wu JH，Xie QL，Chen XJ，et al. Epidermal growth factor receptor（EGFR） and its signal transduction. Chin Bulletin Life Science，2006，18（2）：116-122.

4.Sebastian S，Settlenman J，Reshkin SJ，et al. The Complexity of Targeting EGFR Signaling in Cancer：from Expression to Turnover. Biochim Biophys Acta，2006，1766（1）：120-139.

5.Sharma SV，Bell DW，Settleman J，et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer，2007，7（3）：169-181.

6.Lynch TJ，Bell DW，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med，2004，350（21）：2129-2139.

7.Bigner SH，Humphrey PA，Wong AJ，et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res，1990，50（24）：8017-8022.

8.Humphrey PA，Guang LM，Wong AJ，et al. Deletion-mutant epidermal growth factor receptor in human gliomas：effects of type Ⅱ mutation on receptor function. Biochem Biophy Res Commun，1991，178（3）：1413-1420.

9.Lichtner RB，Wiedemuth M，Noeske-Jungblut C，et al. Rapid effects of EGF on cytoskeletal structures and adhesive properties of highly metastatic rat mammary adenocarcinoma cells.Clin Exp Metastasis，1993，11（1）：113-125.

10.Meert AP，Martin B，Delmotte P，et al. The role of EGFR expression on patient survival in lung cancer：a systematic review with meta-analysis.Eur Respir J，2002，20（4）：975-981.

11.Brabender J，Danenberg KD，Metzger R，et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.Clin Cancer Res，2001，7（7）：1850-1855.

12.Rusch V，Klimstra D，Venkatraman E，et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.Clin Cancer Res，1997，3（4）：515-522.

13.Damstrup L，Wandahl-Pedersen M，Bastholm L，et al. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int J Cancer，2002，97（1）：7-14.

14.Rusch V，Klimstr D，Linkov I，et al. Aberrant expression of p53 if the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res，1995，55（66）：1365-1372.

15.Hsieh ET，Shepherd RA，Tsao MS. Coexpression of epidermal growth factor receptor and transforming growth factor in dependent of ras mutations in lung cancinoma. Lung Cancer，2000，29（2）：151-157.

16.Scordella R，Bell DW，Haber DA，et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptic pathways. Science，2004，305（5687）：1163-1167.

17.Rosell R，Daniel C，Ramlau R，et al. Randomized phase Ⅱstudy of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressiong advanced non-small-cell lung cancer. Ann Oncol，2008，19（2）：362-369.

18.Cappuzzo F，Hirsch，Rossi E，et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst，2005，97（9）：634-655.

19.Bell DW，Gore I，Okimoto RA，et al. Inherited susceptibility to lung cancer may be associated with the T790 drug resistance mutation in EGFR. Nat Genet，2005，37（12）：1315-1316.

20.Oxnard GR，Arcila ME，Sima CS，et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer：distinct natural history of patients with tumors harboring the T790M mutation.Clin Cancer Res，2011，17（6）：1616-1622.

21.Turke AB，Zejnullahu K，Wu YL，et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell，2010，17（1）：77-88.

22.Zhu CQ，Cunha SG，Ding K，et al.Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study Br.21.J Clin Oncol 2008，26（26）：4268-4275.